International Journal of Hepatology最新文献

{"title":"Prognostic Factors of Radiofrequency Ablation plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis.","authors":"Ky Thai Doan,&nbsp;Long Nguyễn Việt,&nbsp;Thinh Nguyen Tien,&nbsp;Binh Nguyen Canh,&nbsp;Hoai Ngo Thi,&nbsp;Ngoc Nguyen Thanh,&nbsp;Bieu Bui Quang,&nbsp;Quang Le Van,&nbsp;Hyun Woong Lee,&nbsp;Bang Mai Hong","doi":"10.1155/2020/8836922","DOIUrl":"https://doi.org/10.1155/2020/8836922","url":null,"abstract":"<p><strong>Introduction: </strong>Survival outcomes in patients with unresectable colorectal cancer (CRC) liver metastasis treated by radiofrequency ablation (RFA) combined with systemic chemotherapy and correlation with potential prognostic factors were investigated. <i>Material and Methods</i>. A retrospective cohort study was conducted on 61 CRC patients with unresectable liver metastasis who underwent liver tumor-directed percutaneous RFA combined with conventional systemic chemotherapy between October 2013 and September 2018. Survival analyses were conducted using the Kaplan-Meier method, and the log-rank test was used to characterize differences in the median survival time and the 1-year, 3-year, and 5-year overall survival rates of subgroups to identify prognostic factors.</p><p><strong>Results: </strong>Median overall survival and progression-free survival of all patients were 32 and 14 months, respectively. The cumulative survival rates at 1-, 3-, and 5-years were 93.2%; 44.5%, and 38.2%, respectively. Univariate analysis revealed that pre-RFA serum CEA levels, Eastern Cooperative Oncology Group (ECOG) status, number of liver lesions, the size of the largest lesion, and the total lesion size were prognostic factors. However, multivariate analysis demonstrated that only the number of liver lesions and the size of the largest lesion were independent prognostic factors for survival.</p><p><strong>Conclusion: </strong>RFA plus systemic chemotherapy provides an encouraging survival outcome for patients with unresectable CRC liver metastasis. Multivariate analysis demonstrated that the number and size of liver metastatic lesions are independent prognostic factors for survival.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"8836922"},"PeriodicalIF":1.8,"publicationDate":"2020-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/8836922","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38767681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The High Prevalence of Negative Hepatitis B Surface Antibody (Anti-HBs) among Pregnant Women in Bandung, Indonesia: A Community-Based Study.","authors":"Dolvy Girawan,&nbsp;Raden T D Judistiani,&nbsp;Nelly A Risan,&nbsp;Muhammad B Bestari,&nbsp;Eka S Nugraha,&nbsp;Yudith S Ermaya,&nbsp;Dwi Prasetyo","doi":"10.1155/2020/3414869","DOIUrl":"https://doi.org/10.1155/2020/3414869","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis B virus (HBV) infection is a disease that creates a high global burden by affecting approximately 3.5% of the total world population. The main transmission of this disease is from mother to child (MTCT). HBV vaccination program was already initiated in Indonesia in 1987. However, after three decades, the HBV infection prevalence stays stagnant. This study aimed to explore the seroprevalence of HBV markers and the attributable risk factors of pregnant women at risk of transmitting HBV to their offspring.</p><p><strong>Method: </strong>A cross-sectional study was conducted on pregnant women from primary midwifery and obstetric clinics across Bandung, Indonesia, to assess the HBsAg, anti-HBc, and anti-HBs serological markers. Questionnaire-based interviews were used to obtain the sociodemographic determinants. Logistic regression was applied to assess the association of each determinant factor to positive HBsAg or negative anti-HBs as a dependent variable, which was then reported as odds ratios (OR).</p><p><strong>Results: </strong>A total of 196 subjects were recruited with 12/196 (6.1%) of them were positive HBsAg. After exclusions of those with positive HBsAg and anti-HBc, 24/175 (13.7%) women were isolated as positive anti-HBs, leaving 151/175 (86.3%) women with negative anti-HBs who were susceptible to HBV infection. Low body mass index (BMI) less than 18.5 kg/m² was a risk factor for positive HBsAg with OR = 5.850 (95% CI 1.466-23.34), <i>p</i> = 0.012. Nevertheless, no significant determinant factor was associated with negative anti-HBs.</p><p><strong>Conclusion: </strong>Most pregnant women in Bandung, Indonesia, are susceptible to HBV infection, as marked by the negative anti-HBs status.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"3414869"},"PeriodicalIF":1.8,"publicationDate":"2020-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/3414869","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38554084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocyte and Islet Cell Cotransplantation on Poly-L-Lactide Matrix for the Treatment of Liver Cirrhosis.","authors":"Siufui Hendrawan, Jennifer Lheman, Nuraeni, Ursula Weber, Hans Ulrich Baer","doi":"10.1155/2020/5410359","DOIUrl":"10.1155/2020/5410359","url":null,"abstract":"<p><p>The human autologous hepatocyte matrix implant is a promising alternative procedure to counter liver damage. We assessed the outcome of human hepatocytes isolation from cirrhotic liver compared to the clinical and histological scores of disease severity. A total of 11 patients with various clinical scores (CTP and MELD) and histological score (Metavir, fibrosis) of liver cirrhosis were included in the hepatocyte matrix implant clinical phase I study. The liver segment and pancreatic tissue were harvested from each patient, and hepatocytes and cells of islets of Langerhans were isolated. The freshly isolated human hepatocytes were coseeded with the islet cells onto poly(l-lactic acid) (PLLA) scaffolds, cultured, and transplanted back into the patient. Human hepatocytes were isolated from 11 cirrhotic liver specimens with a resulting yield of 1.4 ± 0.5 × 10⁶ cells per gram of the liver specimen and a viability rate of 52 ± 13%. It was found that the yield and viability of the liver cells were not correlated with the clinical and histological scores of the liver cirrhosis. A correlation was found between the hepatocyte yield obtained and the average number of hepatocytes counted in 10 microscopic fields of view. More viable cells were obtained from cirrhotic livers caused by chronic hepatitis B as compared to chronic hepatitis C in the same MELD score range. There was no correlation between the clinical and histological disease severity scores of liver cirrhosis and the outcome of hepatocytes isolation. It seems that the yield could depend on the type of hepatitis underlying the cirrhotic tissue. The study was registered at www.clinicaltrial.gov with the study identifier: NCT01335568.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"5410359"},"PeriodicalIF":1.8,"publicationDate":"2020-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38640778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelial Dysfunction, a Marker of Atherosclerosis, Is Independent of Metabolic Syndrome in NAFLD Patients.","authors":"Jimmy Narayan,&nbsp;Haribhakti Seba Das,&nbsp;Preetam Nath,&nbsp;Ayaskanta Singh,&nbsp;Debakanta Mishra,&nbsp;Pradeep Kumar Padhi,&nbsp;Shivaram Prasad Singh","doi":"10.1155/2020/1825142","DOIUrl":"https://doi.org/10.1155/2020/1825142","url":null,"abstract":"<p><strong>Background: </strong>The study was designed to assess cardiovascular risk factors flow-mediated dilatation % (FMD%) and carotid intima-media thickness (CIMT) in NAFLD.</p><p><strong>Methods: </strong>126 NAFLD subjects and 31 chronic hepatitis B (CHB) controls were studied. Measuring carotid intima-media thickness (CIMT) and the flow-mediated dilatation % (FMD%) by brachial artery Doppler ultrasound were used to assess atherosclerosis. The risk of cardiac events at 10 years (ROCE 10) was estimated by the Prospective Cardiovascular Munster Study (PROCAM) score.</p><p><strong>Results: </strong>58 of 126 NAFLD have coexistent metabolic syndrome. Mean CIMT was 0.73 ± 0.041 mm among NAFLD with MS, 0.66 ± 0.016 mm among NAFLD without MS, and 0.66 ± 0.037 in controls CHB patients. FMD% in NAFLD with MS was 10.43 ± 3.134%, but was 8.56 ± 3.581% in NAFLD without MS and 17.78 ± 6.051% in controls. PROCAM score of NAFLD with MS was 46.95 ± 6.509 while in NAFLD without MS was 38.2 ± 3.738. Controls had a PROCAM score of 38.13 ± 5.755. ROCE 10 in NAFLD with MS was 13.64 ± 8.568 while NAFLD without MS was 5.55 ± 1.949. Controls have a ROCE 10 of 5.95 ± 3.973. Post hoc analysis showed CIMT was dependent upon MS while FMD% was different between all subgroups hence independent of metabolic syndrome.</p><p><strong>Conclusion: </strong>The markers of endothelial dysfunction are significantly higher in patients with NAFLD than controls.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"1825142"},"PeriodicalIF":1.8,"publicationDate":"2020-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/1825142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38212375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective.","authors":"Meseret Derbew Molla,&nbsp;Gashaw Dessie,&nbsp;Yonas Akalu,&nbsp;Birhanu Ayelign","doi":"10.1155/2020/2374615","DOIUrl":"https://doi.org/10.1155/2020/2374615","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is an aggressive primary hepatic malignancy with a significant morbidity and mortality rate. Although chemotherapy along with surgical incision is believed to be an effective therapeutic approach, to date recurrence is being lifted a major concern. Thus, identifying another best therapeutic approach is becoming the main aim of physicians and scholars. In support of this, recently, several studies reported a significant observation of Sirtuin1 (SIRT1) overexpression in the malignant tumor cells, including HCC. As a result, they believed that overexpression of SIRT1 may have an effect on the progression of HCC by targeting growth and/or apoptotic controlling transcriptional factors/signaling pathways. Similarly, other reports confirmed that SIRT1 inhibition had a direct or indirect role in the control of tumor cell growth and metastasis. Therefore, inhibiting the expression and activity of SIRT1 might have a therapeutic effect to handle HCC. However, there are a limited number of reviews regarding the issue, and here, we summarized hepatocellular expression of SIRT1 and its role on HCC progression.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"2374615"},"PeriodicalIF":1.8,"publicationDate":"2020-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/2374615","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38109789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines?","authors":"Baba Sulemana Mohammed, Matthew Aidoo","doi":"10.1155/2020/9750194","DOIUrl":"10.1155/2020/9750194","url":null,"abstract":"<p><p>The diverse influence of liver function on drug disposition can lead health-care practitioners to inappropriate drug selection, inappropriate drug dosing, or some level of therapeutic negativism. The aim of this study was to assess how drug prescribing in patients with liver cirrhosis at the Tamale Teaching Hospital comply with recommendations of pharmacotherapy and safety guidelines. A prospective cross-sectional study was conducted from February to July, 2019, at the medical ward of the Tamale Teaching Hospital. A total of 152 liver cirrhotic patients were included in this study. Common etiologies for liver cirrhosis were chronic hepatitis B 80 (52.6%) and chronic hepatitis C 30 (19.7%); about 12.5% of etiologies were unknown. Of the 1842 prescription issued, 69% (1270/1842) were compliant. Of the 572 noncompliant prescriptions, about 32% (183/572) were due to pharmacotherapy and 68% (389/572) due to safety guideline recommendations. There was a substantial number (31%) of prescription noncompliance with recommendations for pharmacotherapy and safety guidelines in liver cirrhotic patients at the tertiary hospital in northern Ghana. Prescribers need to be conscious of the role of the liver in drug elimination and prescribe as recommended by guidelines.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"9750194"},"PeriodicalIF":1.5,"publicationDate":"2020-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38059074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Knowledge of Hepatitis B Virus Infection among Pregnant Women in the Ningo-Prampram District, Ghana.","authors":"Precious Kwablah Kwadzokpui,&nbsp;Elliot Elikplim Akorsu,&nbsp;Albert Abaka-Yawson,&nbsp;Solomon Sosu Quarshie,&nbsp;Stephen Adomako Amankwah,&nbsp;Philip Apraku Tawiah","doi":"10.1155/2020/7965146","DOIUrl":"https://doi.org/10.1155/2020/7965146","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis B virus (HBV) infection has been suggested to play a role in various adverse birth outcomes. The study determined the prevalence as well as knowledge of hepatitis B virus infection among pregnant women in the Ningo-Prampram District of the Greater Accra Region of Ghana.</p><p><strong>Materials and methods: </strong>A cross-sectional study using simple random sampling technique was used to recruit 213 pregnant women receiving antenatal care in three different health facilities (Prampram Polyclinic (PPC), Dangme Community Hospital (DCH), and Old Ningo Health Center (ONHC)) in the Ningo-Prampram District of Ghana from November 2018 to January 2019. A semi-structured questionnaire was used to collect data which included participants' HBsAg test results, sociodemographic and gynaecological characteristics, and their level of knowledge on HBV infection. Knowledge of the participants on HBV infection was classified as either excellent, good, or poor based on their cumulative percentage scores from the questionnaire according to Al Rubaish system of classification.</p><p><strong>Results: </strong>Overall low-intermediate prevalence of HBV infection was 3.3%; however, PPC recorded the highest prevalence of 4.0% while DCH and ONHC recorded 2.82% and 2.50%, respectively. Statistically significant association was observed between HBV infection and the health facility. Majority (77.40%) of the study participants had poor knowledge on HBV infection while only 14 (6.57%) had excellent knowledge on HBV. Regarding excellent knowledge, 8 (11.0%) among the participants were demonstrated by the majority of those who received antenatal care from DCH. Generally, knowledge on HBV and the infection was poor among the study participants. Knowledge on HBV infection was found to be associated with residential status (<i>p</i> = 0.006), educational level (<i>p</i> < 0.001), occupation (<i>p</i> < 0.001), and gestational period (<i>p</i> < 0.001). Participant's knowledge was also significantly associated with the health facility (<i>p</i> = 0.027).</p><p><strong>Conclusion: </strong>HBV infection among pregnant women is prevalent in the Ningo-Prampram District even though the prevalence is not very high. The majority of pregnant women in the Ningo-Prampram District inadequate knowledge on HBV infection and it mode of transmission. Intensive public health education on the HBV infection is required in the district to help prevent and manage future transmissions as well as inform the population about the negative side effects of the virus and the need to prevent it by way of vaccination.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"7965146"},"PeriodicalIF":1.8,"publicationDate":"2020-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/7965146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37937981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isoniazid and Rifampicin Produce Hepatic Fibrosis through an Oxidative Stress-Dependent Mechanism.","authors":"Ayan Biswas,&nbsp;Suman Santra,&nbsp;Debasree Bishnu,&nbsp;Gopal Krishna Dhali,&nbsp;Abhijit Chowdhury,&nbsp;Amal Santra","doi":"10.1155/2020/6987295","DOIUrl":"https://doi.org/10.1155/2020/6987295","url":null,"abstract":"<p><strong>Methods: </strong>A combined dose of INH (50 mg) and RMP (100 mg) per kg body weight per day was administered to mice by oral gavage, 6 days a week, for 4 to 24 weeks for the assessment of liver injury, oxidative stress, and development of hepatic fibrosis, including demonstration of changes in key fibrogenesis linked pathways and mediators.</p><p><strong>Results: </strong>Progressive increase in markers of hepatic stellate cell (HSC) activation associated with changes in matrix turnover was observed between 12 and 24 weeks of INH-RMP treatment along with the elevation of liver collagen content and significant periportal fibrosis. These were associated with concurrent apoptosis of the hepatocytes, increase in hepatic cytochrome P450 2E1 (CYP2E1), NADPH oxidase (NOX) activity, and development of hepatic oxidative stress.</p><p><strong>Conclusions: </strong>INH-RMP can activate HSC through generation of NOX-mediated oxidative stress, leading to the development of liver fibrosis.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"6987295"},"PeriodicalIF":1.8,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6987295","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37904618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Many Difficulties and Subtleties in the Cognitive Assessment of Chronic Hepatitis C Infection.","authors":"Jefferson Abrantes,&nbsp;Daniel Simplicio Torres,&nbsp;Carlos Eduardo Brandão-Mello","doi":"10.1155/2020/9675235","DOIUrl":"https://doi.org/10.1155/2020/9675235","url":null,"abstract":"<p><p>Since the discovery of HCV in 1989, several diseases have been related to chronic infection by this virus. Often, patients with hepatitis C virus (HCV) complain of cognitive impairment even before the development of hepatic cirrhosis, which they described as \"brain fog.\" Several studies have proposed a link between chronic HCV infection and the development of cognitive alterations, but the inclusion of confounding factors in their samples significantly limits the analysis of the results. In this article, we will give an overview about cognitive dysfunction in patients with HCV.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"9675235"},"PeriodicalIF":1.8,"publicationDate":"2020-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9675235","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease.","authors":"Alireza Meighani,&nbsp;Maryam Alimirah,&nbsp;Mayur Ramesh,&nbsp;Reena Salgia","doi":"10.1155/2020/1874570","DOIUrl":"https://doi.org/10.1155/2020/1874570","url":null,"abstract":"<p><strong>Background: </strong>Fecal microbiota transplantation (FMT) is a well-established therapeutic option for patients with antibiotic resistant <i>Clostridioides difficile</i> infection (CDI). However, the efficacy of FMT in patients with chronic liver disease remains elusive.</p><p><strong>Aims: </strong>We studied the effect of FMT on chronic liver disease (CLD) patients with CDI at our tertiary medical center.</p><p><strong>Methods: </strong>A cohort of all patients who received FMT from December 2012 to May 2014 for refractory or recurrent CDI was identified. Patients were monitored for a year after FMT. Descriptive analysis was conducted to compare the effect of FMT in patients with and without CLD.</p><p><strong>Results: </strong>A total of 201 patients with CDI received FMT, 14 of which had a history of CLD. Nine of these patients exhibited cirrhosis of the liver with a mean Child-Turcotte-Pugh score of 8. CDI development in these patients was associated with recent exposure to antibiotics and was observed to be significantly different between both groups (17% of CLD patients vs. 58% in the general cohort, <i>p</i> = 0.01). Four patients with CLD received >1 FMT, of which 2 did not respond to treatment. There was no significant difference between patients with liver disease and the rest of the cohort with regard to FMT response (12/14 (87%) vs. 164/187 (88%), <i>p</i> = 0.01). Four patients with CLD received >1 FMT, of which 2 did not respond to treatment. There was no significant difference between patients with liver disease and the rest of the cohort with regard to FMT response (12/14 (87%) vs. 164/187 (88%).</p><p><strong>Conclusion: </strong>FMT is a safe and effective therapy against CDI for patients with CLD and cirrhosis.</p>","PeriodicalId":46297,"journal":{"name":"International Journal of Hepatology","volume":"2020 ","pages":"1874570"},"PeriodicalIF":1.8,"publicationDate":"2020-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/1874570","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37634072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}